Hydralazine as Demethylating Agent in Breast Cancer
Status:
Withdrawn
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This study will be conducted as a phase I/II clinical trial. In addition to determining the
maximum tolerated dose (MTD) of hydralazine, the phase I trial will be performed to identify
unexpected toxicities that may occur when hydralazine is used in conjunction with neoadjuvant
chemotherapy in normotensive women with breast cancer. Once the phase I trial is successfully
completed, the phase II trial to evaluate the efficacy of hydralazine in producing a
demethylation effect will begin.